Stockscreener 앱 받기
72.70
4.33%
3.02
시간 외 거래:
72.70
전일 마감가:
$69.68
열려 있는:
$70.68
하루 거래량:
2.94M
Relative Volume:
1.33
시가총액:
$12.01B
수익:
$943.38M
순이익/손실:
$-380.99M
주가수익비율:
-29.47
EPS:
-2.4667
순현금흐름:
$-325.67M
1주 성능:
+1.44%
1개월 성능:
-10.17%
6개월 성능:
+15.45%
1년 성능:
+125.29%
1일 변동 폭
$70.68
$73.61
1주일 범위
$68.90
$73.61
52주 변동 폭
$23.95
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
72.70 | 11.51B | 943.38M | -380.99M | -325.67M | -2.4667 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-10-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2025-09-03 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
IONS: HC Wainwright & Co. Raises Price Target to $120 | IONS Sto - GuruFocus
Stifel raises Ionis Pharmaceuticals price target on drug pricing By Investing.com - Investing.com India
IONS: Needham Raises Price Target for Ionis Pharmaceuticals | IO - GuruFocus
Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright - MarketBeat
Wolfe Research reiterates Ionis stock rating on pricing strategy - Investing.com
Patterns Watch: Why is Ionis Pharmaceuticals Inc stock going upAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - The Globe and Mail
Aug Big Picture: Does Ionis Pharmaceuticals Inc outperform in volatile marketsSwing Trade & Weekly Chart Analysis and Guides - baoquankhu1.vn
When Insider Selling Is a Good Thing: 2 Stocks to Watch - Investing.com
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
FDA accepts zilganersen application for Alexander disease review By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (IONS) Gains FDA Priority Review for Zilga - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $412,477.64 in Stock - MarketBeat
Ionis Pharma EVP Schneider sells $412k in shares By Investing.com - Investing.com South Africa
Ionis Pharma EVP Schneider sells $412k in shares - Investing.com
Ionis gains priority review for zilganersen for Alexander disease - MSN
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - BioSpace
FDA Prioritizes Review of Ionis Pharmaceuticals' Drug for Alexan - GuruFocus
Ionis Pharmaceuticals, Inc. recently announced that its New Drug Application (NDA) for Zilganersen, a new treatment developed for Alexander disease (AxD), has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA). - Bitget
FDA accepts zilganersen application for Alexander disease review - Investing.com
Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Ionis Board Shakeup And Valuation Gap Draw Investor Attention - Yahoo Finance
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative (NASDAQ:IONS) - Seeking Alpha
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
Affiliate files Form 144 to sell shares — IONS (NASDAQ: IONS) - Stock Titan
Why Ionis Pharmaceuticals’ (IONS) 2026 catalyst pipeline supported Leerink’s higher target - MSN
Hudson Bay Capital Management LP Decreases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Groupama Asset Managment - MarketBeat
Insider Sell: Elizabeth Hougen Sells 225,220 Shares of Ionis Pha - GuruFocus
Did Ionis Pharmaceuticals' (IONS) Board Refresh and Return of Peter Reikes Just Shift Its Investment Narrative? - simplywall.st
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 215,048 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $744,692.12 in Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ: IONS) CFO sells 225,220 shares after option exercises - Stock Titan
Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Airsculpt Technologies (AIRS) and NRX Pharmaceuticals (NRXP) - The Globe and Mail
BlueCrest Capital Management Ltd Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Alpine Global Management LLC Acquires 30,463 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Retail Trends: Can Ionis Pharmaceuticals Inc outperform in the next rally2026 Rallies & Stock Market Timing Techniques - baoquankhu1.vn
Bamco Inc. NY Makes New $1.64 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - National Today
Goldman Sachs Upgrades Ionis Pharmaceuticals (IONS) - MSN
IONS (IONS) Form 144 notices proposed resale of 225,200 shares - Stock Titan
Ionis Pharmaceuticals (IONS) Among Most Oversold Healthcare Stocks - GuruFocus
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat
BlueCrest Capital Management Ltd Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Cinctive Capital Management LP Invests $11.37 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Boone Capital Management LLC Takes $27.34 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Baker BROS. Advisors LP Makes New $37.08 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):